ArticleJNCI cancer spectrum2020
Subtyping Cutaneous Melanoma Matters.
Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Utilizing relative survival to investigate melanoma subtypes across intersectional demographics: a Surveillance, Epidemiology, and End Results (SEER) cohort study.Skin health and disease · 2026Article
- The role of vitamin C in melanoma cell death via activation of cytochrome C and TNF-α protein expression.Scientific reports · 2025Article
- Histopathological Subtypes of Cutaneous Melanoma: Prognostic and Molecular Implications.Cureus · 2025Review
- Screening and novel diagnostic technologies for melanoma: an update.Melanoma management · 2025Review
- Article
- Proteomic and metabolomic profiles of plasma-derived Extracellular Vesicles differentiate melanoma patients from healthy controls.Translational oncology · 2024Article
- Article
- Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- The Role of the PTEN Tumor Suppressor Gene and Its Anti-Angiogenic Activity in Melanoma and Other Cancers.Molecules (Basel, Switzerland) · 2024Review
- Amelanotic Malignant Melanoma: A Case Report.Cureus · 2023Article
- Clinicopathological Profile of a Cohort of Patients With Malignant Melanoma in the United Kingdom.Cureus · 2023Article
- Analysis and prediction of 5-year survival in patients with cutaneous melanoma: a model-based period analysis.Frontiers in endocrinology · 2023Article
- Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma.Journal of cancer research and clinical oncology · 2022Article
- Gene Expression Patterns of Osteopontin Isoforms and Integrins in Malignant Melanoma.Pathology oncology research : POR · 2022Article
- Histopathological Characteristics of Cutaneous Melanoma in Isfahan, Iran, from 2013 to 2018.Journal of skin cancer · 2022Article
- Multivariate analysis of prognostic factors in patients with nodular melanoma.Journal of cancer research and clinical oncology · 2021Article
- The fusion of light and immunity: Advancements in photoimmunotherapy for melanoma.Photochemistry and photobiologyReview
- Proposal for the applicability of modified Breslow (measured from the basal membrane) as a predictor of survival and sentinel lymph node outcome in patients with cutaneous melanoma.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur aim was to investigate the role of melanoma subtype on survival and focus on the effects stratified by Breslow thickness and ulceration status.
methodsPatients with cutaneous melanoma stage I, II, or III diagnosed between 2000 and 2014 were derived from the Dutch Nationwide Pathology Registry and overall survival data from the Netherlands Cancer Registry. Patients were followed until 2018. Using multivariable Cox proportional hazards models, hazard ratios were calculated for each melanoma subtype, per Breslow thickness category and ulceration status, and adjusted for age, sex, stage, and localization.
resultsA total of 48 361 patients were included: 79.3% had superficial spreading melanoma (SSM), 14.6% nodular melanoma (NM), 5.2% lentigo maligna melanoma, and 0.9% acral lentiginous melanoma (ALM). In the total patient group, using SSM as the reference category, adjusted hazard ratios were 1.06 (95% confidence interval [CI] = 1.01 to 1.12) for NM, 1.02 (95% CI = 0.93 to 1.13) for lentigo maligna melanoma, and 1.26 (95% = CI 1.06 to 1.50) for ALM. Among patients with 1.0 mm or less Breslow thickness and no ulceration, NM showed a twofold increased risk (hazard ratio = 1.96, 95% CI = 1.58 to 2.45) compared with SSM. Compared with 1.0 mm or less SSM without ulceration, the hazard ratio for 1.0 mm or less SSM with ulceration was 1.94 (95% CI = 1.55 to 2.44), and the hazard ratio for 1.0 mm or less NM with ulceration was 3.46 (95% CI = 2.17 to 5.50). NM patients with tumors greater than 1.0 mm did not show worse survival than SSM patients with tumors greater than 1.0 mm.
conclusionsIn this large nationwide study, ALM patients showed worse survival than SSM patients. Among patients with melanomas that were thin (1.0 mm or less), NM subtype patients also showed worse survival than SSM patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.